AzTrials
AzTrials

Binge Eating DisorderPhase 2BEDNCT01291173

Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder

A Phase 2 study testing lisdexamfetamine dimesylate (SPD489) in people with Binge Eating Disorder, run by Shire at 31 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week Read more about this study

Who is it for?
Ages 18 to 55 years
Conditions the study is for
Binge Eating Disorder
What is being tested?
lisdexamfetamine dimesylate (SPD489)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
271 participants
Where
31 sitesUnited States
Study dates
10 May 2011to 30 Jan 2012
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Subject meets the following Diagnostic and Statistical Manual of Mental Disorders Fourth Edition - Text Revision (DSM-IV-TR) criteria for a diagnosis of binge eating disorder (BED).
  • Binge eating disorder is of at least moderate severity in which subjects report at least 3 binge eating days per week.
  • Subject has a body mass index (BMI) of >24 and <46.

Who cannot join

  • Subject has concurrent symptoms of bulimia nervosa or anorexia nervosa.
  • Subject is considered a suicide risk or risk to harm others.

Trial locations and contacts

31 sites in 1 country.

31 sites in 1 country

United States31 sites
  • Atlanta Institute of Medicine and Research

    Atlanta, Georgia, 30328

  • FutureSearch Clinical Trials

    Austin, Texas, 78731

  • McLean Hospital

    Belmont, Massachusetts, 02478

  • Southwestern Research, Inc.

    Beverly Hills, California, 90210

  • Boston Clinical Trials

    Boston, Massachusetts, 02135

  • Florida Clinical Research

    Bradenton, Florida, 32408

  • Weight Management Center, Medical University of South Carolina

    Charleston, South Carolina, 29425

  • Charlottesville Medical Research

    Charlottesville, Virginia, 22911

  • Community Research

    Cincinnati, Ohio, 45227

  • Neuropsychiatric Research Institute

    Fargo, North Dakota, 58103

  • Gulfcoast Clinical Research

    Fort Myers, Florida, 33912

  • Drug Development, Inc.

    Houston, Texas, 77081

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida, 32216

  • Scripps Clinical Research Services

    La Jolla, California, 92037

  • Robert Lynn Horne, MD

    Las Vegas, Nevada, 89102

  • Capstone Clinical Research

    Libertyville, Illinois, 60048

  • Clinical Study Centers, LLC

    Little Rock, Arkansas, 72205

  • Lindner City of Hope

    Mason, Ohio, 45040

  • Clinical Neuroscience Solutions, Inc.

    Memphis, Tennessee, 38119

  • Unniversity of Minnesota

    Minneapolis, Minnesota, 55454

  • Louisiana Research Associates, Inc.

    New Orleans, Louisiana, 70114

  • Pharmacology Research Institute

    Newport Beach, California, 92660

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida, 32806

  • Vince and Assoc. Research

    Overland Park, Kansas, 66212

  • Clinical Trials Technology, Inc.

    Prairie Village, Kansas, 66206

  • Wake Research Associates

    Raleigh, North Carolina, 27612

  • Marc Hertzman, MD, PC

    Rockville, Maryland, 20852

  • PCSD - Feighner Research

    San Diego, California, 92108

  • Carman Research

    Smyrna, Georgia, 30080

  • Weight Disorders Washington University School of Medicine, Dept of Psychiatry

    St Louis, Missouri, 63110

  • Richmond Behavioral Associates

    Staten Island, New York, 10312

Other trials in United States

About this study

Official title: A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder

To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week

Being tested
lisdexamfetamine dimesylate (SPD489), Placebo
Medical subject headings
Binge-Eating Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • lisdexamfetamine dimesylate (SPD489)Drug

    Also called LDX, Vyvanse

    SPD489-30mg capsules taken once daily for up to 11 weeks

  • lisdexamfetamine dimesylate (SPD489)Drug

    Also called LDX, Vyvanse

    SPD489 50mg capsules taken once-daily for up to 11 weeks

  • lisdexamfetamine dimesylate (SPD489)Drug

    Also called LDX, Vyvanse

    SPD489 70mg capsule taken once-daily for up to 11 weeks

  • PlaceboDrug

    Placebo capsule taken once daily for up to 11 weeks

Study groups in NCT01291173
Study groupRoleWhat they receive
SPD489 30 mgExperimentalNot described
Receives: Drug: lisdexamfetamine dimesylate (SPD489)
SPD489 50 mgExperimentalNot described
Receives: Drug: lisdexamfetamine dimesylate (SPD489)
SPD489 70 mgExperimentalNot described
Receives: Drug: lisdexamfetamine dimesylate (SPD489)
PlaceboPlacebo comparatorNot described
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Log Transformed Binge Days Per Week at Week 11

    Binge day is defined as a day during which at least 1 binge episode occurs.

    Measured: Baseline and week 11

Secondary outcomes (13)
  1. Change From Baseline in the Number of Binge Episodes Per Week at Up to 11 Weeks

    The number of binge episodes per week as assessed by clinical interview based on subject diary.

    Measured: Baseline and up to 11 weeks

  2. 1-Week Binge Response, Last Observation Carried Forward (LOCF)

    The 1-week binge response was defined as either a 1-week remission (a 100% reduction of binge episodes from baseline [ie, a cessation of binge eating behavior]), or a marked response (75 to <100% reduction in binge episodes from baseline), or a moderate response (50 to <75% reduction in binge episodes from baseline), or a negative/minimal response (<50% reduction in binge episodes from baseline). The 1-week response was determined at the end of the study utilizing a LOCF approach.

    Measured: Last 7 days on study

  3. 4-Week Binge Response

    Subjects are free from binge episodes for 4 weeks.

    Measured: Last 28 days on study

  4. Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Measured: Baseline

  5. Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Up to 11 Weeks

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Measured: up to 11 weeks

  6. Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Up to 11 Weeks

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Measured: Up to 11 weeks

  7. Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score at Week 11

    The YBOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. A score of 0-7 is sub-clinical; 8-15 is mild; 16-23 is moderate; 24-31 is severe; and 32-40 is extreme.

    Measured: Baseline and week 11

  8. Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Score at Week 11

    MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

    Measured: Baseline and week 11

  9. Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score at Week 11

    The HAM-A is a rating scale developed to quantify the severity of anxiety symptomatology. It consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe) with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity, and 25-30 moderate to severe, and 31-56 severe anxiety.

    Measured: Baseline and week 11

  10. Change From Baseline in Eating Inventory Score at Week 11

    The Eating Inventory also known as the Three-Factor Eating Questionnaire is a 51-item self-reported questionnaire intended to assess 3 dimensions of eating behavior: cognitive restraint of eating, disinhibition, and hunger. Cognitive restraint of eating consists of 20 items, disinhibition consists of 16 items, and hunger consists of 15 items. Each item scores either 0 or 1 point for a total score of 0-20 for cognitive restraint of eating, 0-16 for disinhibition, and 0-15 for hunger. A higher score is better for cognitive restraint of eating and lower scores are better for disinhibition and hunger.

    Measured: Baseline and week 11

  11. Change From Baseline in Binge Eating Scale (BES) Score at Week 11

    The BES is a 16-item self-reported questionnaire that is designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. The items are summed, with possible scores ranging from 0 to 46. A score of 27 or higher indicates severe binge-eating problems, and a score of 17 or lower designates no binge-eating problems.

    Measured: Baseline and week 11

  12. Change From Baseline in Barratt Impulsiveness Scale (BIS-11) Total Score at Week 11

    The BIS-11 is a self-reported 30-item questionnaire that measures impulsiveness using a 4-point Likert scale (rarely/never = 1, occasionally = 2, often = 3, almost always/always = 4). A Total Impulsivity score is calculated by summing the scores for each item. Possible scores range from 30 - 120. Higher scores indicate increased impulsiveness.

    Measured: Baseline and week 11

  13. Change From Baseline in Short Form-12 Health Survey (SF-12) Score at Week 11

    The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. There are 8 subscales. Four of the subscales has one-item each; the other 4 have two-items each. For each subscale, a mean value was first computed and transformed to a position on a scale ranging from 0-100 (Z-transformation). The aggregate total scores are then transformed into a mean value ranging from 0 (lowest level of health) to 100 (highest level of health).

    Measured: Baseline and week 11

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Feb 2011 (estimated)
  2. Study start10 May 2011
  3. Primary completion30 Jan 2012
  4. Study completion30 Jan 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
271 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01291173
Sponsor's protocol ID
SPD489-208
Acronym
BED
Status last verified
May 2021
First submitted
4 Feb 2011
Last updated
10 Jun 2021
Data monitoring committee
No

Publications

  • McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, Wang J, Whitaker T, Jonas J, Gasior M. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015 Mar;72(3):235-46. doi: 10.1001/jamapsychiatry.2014.2162.

    PubMed 25587645

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing lisdexamfetamine dimesylate (SPD489) in people with Binge Eating Disorder, run by Shire at 31 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 31 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 31 Dec 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Log Transformed Binge Days Per Week at Week 11 (time frame: Baseline and week 11). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01291173, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in